Distribution of Iron Oxide Core-Titanium Dioxide Shell Nanoparticles in VX2 Tumor Bearing Rabbits Introduced by Two Different Delivery Modalities
Authors:
- Tamer RefaatTRTamer Refaat
- Derek WestDWDerek West
- Samar El AchySASamar El Achy
- Vamsi ParimiVPVamsi Parimi
- Jasmine MayJMJasmine May
- Lun XinLXLun Xin
- Kathleen R. HarrisKHKathleen R. Harris
- William LiuWLWilliam Liu
- Michael Beau WanzerMWMichael Beau Wanzer
- Lydia FinneyLFLydia Finney
- Evan MaxeyEMEvan Maxey
- Stefan VogtSVStefan Vogt
Open Access
- 3 August 2016
- journal article
- research article
- Published by MDPI AG in Nanomaterials
- Vol. 6 (8) , 143
Abstract
This work compares intravenous (IV) versus fluoroscopy-guided transarterial intra-catheter (IC) delivery of iron oxide core-titanium dioxide shell nanoparticles (NPs) in vivo in VX2 model of liver cancer in rabbits. NPs coated with glucose and decorated with a peptide sequence from cortactin were administered to animals with developed VX2 liver cancer. Two hours after NPs delivery tumors, normal liver, kidney, lung and spleen tissues were harvested and used for a series on histological and elemental analysis tests. Quantification of NPs in tissues was done both by bulk inductively coupled plasma mass spectrometry (ICP-MS) analysis and by hard X-ray fluorescence microscopy. Both IV and IC NPs injection are feasible modalities for delivering NPs to VX2 liver tumors with comparable tumor accumulation. It is possible that this is an outcome of the fact that VX2 tumors are highly vascularized and hemorrhagic, and therefore enhanced permeability and retention (EPR) plays the most significant role in accumulation of nanoparticles in tumor tissue. It is, however, interesting to note that IV delivery led to increased sequestration of NPs by spleen and normal liver tissue, while IC delivery lead to more NP positive Kupffer cells. This difference is most likely a direct outcome of blood flow dynamics. Armed with this knowledge about nanoparticle delivery, we plan to test them as radiosensitizers in the future.Keywords
Funding Information
- National Institutes of Health (RO1EB002100, U54CA151880, R25CA132822)
- U.S. Department of Energy (DE-AC02-06CH11357)
This publication has 27 references indexed in Scilit:
- Efficient drug-delivery using magnetic nanoparticles — biodistribution and therapeutic effects in tumour bearing rabbitsNanomedicine: Nanotechnology, Biology and Medicine, 2013
- Embolization of liver tumors: Past, present and futureWorld Journal of Radiology, 2012
- NCI's provocative questions on cancer: some answers to ignite discussionOncotarget, 2011
- Intraprocedural diffusion‐weighted PROPELLER MRI to guide percutaneous biopsy needle placement within rabbit VX2 liver tumorsJournal of Magnetic Resonance Imaging, 2009
- MR Tracking of Iron-labeled Glass Radioembolization Microspheres during Transcatheter Delivery to Rabbit VX2 Liver Tumors: Feasibility StudyRadiology, 2008
- Liver Tumors: Monitoring Embolization in Rabbits with VX2 Tumors—Transcatheter Intraarterial First-Pass Perfusion MR ImagingRadiology, 2007
- Comparison of Transcatheter Intraarterial Perfusion MR Imaging and Fluorescent Microsphere Perfusion Measurements during Transcatheter Arterial Embolization of Rabbit Liver TumorsJournal of Vascular and Interventional Radiology, 2007
- Comparison between intravenous and intraarterial contrast injections for dynamic 3D MRI of liver tumors in the VX2 rabbit modelJournal of Magnetic Resonance Imaging, 2006
- Real-time MRI Monitoring of Transcatheter Hepatic Artery Contrast Agent Delivery in Rabbits1Academic Radiology, 2005
- A Study of Embolizing Materials for Chemo-embolization Therapy of Hepatocellular Carcinoma: Effects of Particle Size and Dose on Chitin-Containing cis-Diamminedichloroplatinum(II) Albumin Microsphere Antitumor Activity in VX2 Hepatic Tumor Model Rabbits.Biological and Pharmaceutical Bulletin, 1994